The effect of sunitinib on immune subsets in metastatic clear cell renal cancer

Urologia Internationalis

Volumn 86, Issue 1, 2011, Pages 53-59

  Powles, Thomas ^a   Chowdhury, Simon ^b   Bower, Mark ^a   Saunders, Nataile ^a   Lim, Louise ^a   Shamash, Jonathan ^a   Sarwar, Naveed ^a   Sadev, Anju ^a   Peters, John ^d   Green, James ^d   Boleti, Katia ^c   Augwal, Samir ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Immune parameters; Renal cancer; Sunitinib

Indexed keywords

EVEROLIMUS; LACTATE DEHYDROGENASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CD19+ B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD56+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INNATE IMMUNITY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LETHARGY; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE COUNT; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER T CELL; NEPHRECTOMY; NEUTROPENIC SEPSIS; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SEPSIS; SIDE EFFECT; T LYMPHOCYTE SUBPOPULATION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; TREATMENT OUTCOME;

EID: 79951810777     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319498     Document Type: Article

References (15)

1. McDermott DF: Immunotherapy of metastatic renal cell carcinoma. Cancer 2009; 115(suppl 10):2298-2305.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124. (Pubitemid 46089672)
3. Chung EK, Stadler WM: Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. Clin Genitourin Cancer 2008; 6(suppl 1):S22-S28.
4. Atkins MB: Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2- based immunotherapy. Med Oncol 2009; 26(suppl 1):18-22.
5. Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, Fayyad R, Figlin RA: Phase I trial of sunitinib malate plus interferon- alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009; 7: 28-33.
6. Kroog GS, Feldman DR, Kondagunta GV, Ginsberg PM, Fischer MJ, Trinos S, Patil NM, Ishill NM, Motzer RJ: Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma (abstract 5037). J Clin Oncol 2009; 27( suppl):15s.
7. Reck MN, Frickhofen U, Gatzemeier H, Fuhr S, Lanzalone MJ, Lechuga E, Wang R, Chao E, Felip R: A phase I dose escalation study of sunitinib in combination with gemcitabine + cisplatin for advanced non-small cell lung cancer (NSCLC). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25(suppl):18057.
8. Zhu AX, Duda DG, Sahani DV, Jain RK: Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 2009; 15: 263-268.
9. Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA: Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009; 115: 3571-3580.
10. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-463. (Pubitemid 41079774)
11. Powles T, Imami N, Nelson M, Gazzard BG, Bower M: Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16: 531-536. (Pubitemid 34218847)
12. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-2157.
13. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, Bukowski R: Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14: 6674-6682.
14. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-3748.
15. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV: Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13: 2643-2650. (Pubitemid 46788031)